What was the market valuation of the US g protein-coupled-receptors market in 2024?

The market valuation was $7.02 Billion in 2024. Read More

What is the projected market valuation for the US g protein-coupled-receptors market by 2035?

The projected valuation for 2035 is $12.25 Billion. Read More

What is the expected CAGR for the US g protein-coupled-receptors market during the forecast period 2025 - 2035?

The expected CAGR during this period is 5.19%. Read More

Which therapeutic applications are expected to drive growth in the US g protein-coupled-receptors market?

Key therapeutic applications include Neurological Disorders, Cancer, and Cardiovascular Diseases, with valuations ranging from $1.2 Billion to $3.0 Billion. Read More

What are the leading companies in the US g protein-coupled-receptors market?

Key players include Pfizer Inc, Johnson & Johnson, and Merck & Co Inc. Read More

How does the market for Class A g protein-coupled-receptors compare to other classes?

Class A g protein-coupled-receptors had a valuation of $2.81 Billion in 2024, projected to reach $4.92 Billion by 2035. Read More

What is the market size for the biotechnology segment in the US g protein-coupled-receptors market?

The biotechnology segment was valued at $1.75 Billion in 2024 and is expected to grow to $3.0 Billion by 2035. Read More

What research types are contributing to the US g protein-coupled-receptors market growth?

Basic Research, Applied Research, and Clinical Research are key contributors, with valuations ranging from $2.1 Billion to $4.75 Billion. Read More

What is the market size for Frizzled g protein-coupled-receptors?

Frizzled g protein-coupled-receptors had a valuation of $0.7 Billion in 2024, projected to increase to $1.22 Billion by 2035. Read More

Which end-use segment is expected to dominate the US g protein-coupled-receptors market?

The Pharmaceuticals segment is expected to dominate, with a valuation of $2.81 Billion in 2024, projected to reach $4.75 Billion by 2035. Read More

US G Protein Coupled Receptors Market

ID: MRFR/LS/18110-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

US G Protein-Coupled Receptors Market Research Report By Product Type (cell lines, detection kits, cell culture reagents, ligands), By Assay Type (camp functional assays, calcium functional assays, -arrestin functional assays, radioligand binding and gtps functional assays, internalization assays, trafficking assays, other assays) and By Application (cancer research, cns research, metabolic research, cardiovascular research, respiratory research, inflammation research, other application) - Growth & Industry Forecast 2025 To 2035

US G Protein Coupled Receptors Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Billion)
  1. 4.1.1 Class A
  2. 4.1.2 Class B
  3. 4.1.3 Class C
  4. 4.1.4 Frizzled
  5. 4.1.5 Tachykinin
2. 4.2 Life Sciences, BY Therapeutic Application (USD Billion)
  1. 4.2.1 Neurological Disorders
  2. 4.2.2 Metabolic Disorders
  3. 4.2.3 Cardiovascular Diseases
  4. 4.2.4 Cancer
  5. 4.2.5 Respiratory Diseases
3. 4.3 Life Sciences, BY End Use (USD Billion)
  1. 4.3.1 Pharmaceuticals
  2. 4.3.2 Biotechnology
  3. 4.3.3 Academic Research
  4. 4.3.4 Contract Research Organizations
4. 4.4 Life Sciences, BY Research Type (USD Billion)
  1. 4.4.1 Basic Research
  2. 4.4.2 Applied Research
  3. 4.4.3 Clinical Research
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis AG (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche Holding AG (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Johnson & Johnson (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca PLC (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eli Lilly and Company (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi SA (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY THERAPEUTIC APPLICATION
4. 6.4 US MARKET ANALYSIS BY END USE
5. 6.5 US MARKET ANALYSIS BY RESEARCH TYPE
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Billion)
14. 6.14 LIFE SCIENCES, BY THERAPEUTIC APPLICATION, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY THERAPEUTIC APPLICATION, 2024 TO 2035 (USD Billion)
16. 6.16 LIFE SCIENCES, BY END USE, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY END USE, 2024 TO 2035 (USD Billion)
18. 6.18 LIFE SCIENCES, BY RESEARCH TYPE, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY RESEARCH TYPE, 2024 TO 2035 (USD Billion)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY THERAPEUTIC APPLICATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.2.4 BY RESEARCH TYPE, 2025-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Life Sciences Market Segmentation

Life Sciences By Type (USD Billion, 2025-2035)

Class A
Class B
Class C
Frizzled
Tachykinin

Life Sciences By Therapeutic Application (USD Billion, 2025-2035)

Neurological Disorders
Metabolic Disorders
Cardiovascular Diseases
Cancer
Respiratory Diseases

Life Sciences By End Use (USD Billion, 2025-2035)

Pharmaceuticals
Biotechnology
Academic Research
Contract Research Organizations

Life Sciences By Research Type (USD Billion, 2025-2035)

Basic Research
Applied Research
Clinical Research

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”